1,721,609 research outputs found
Artery Bypass
Full text linkThe latest diagnostic and therapeutic modalities in the management of coronary artery disease by coronary artery bypass graft surgery and by percutaneous coronary intervention with stenting and in the interventional management of other atherosclerotic vascular disease have led to a reduction in cardiovascular mortality and morbidity. This book entitled Artery Bypass provides an excellent update on these advances which every physician seeing patients with atherosclerotic vascular disease should be familiar with. This book includes 27 chapters written by experts in their topics
Cardiac Arrhythmias
Full text linkThis book is useful for physicians taking care of patients with cardiac arrhythmias and includes six chapters written by experts in their field. Chapter 1 discusses basic mechanisms of cardiac arrhythmias. Chapter 2 discusses the chronobiological aspects of the impact of apnoic episodes on ventricular arrhythmias. Chapter 3 discusses navigation, detection, and tracking during cardiac ablation interventions. Chapter 4 discusses epidemiology and pathophysiology of ventricular arrhythmias in several noncardiac diseases, methods used to assess arrhythmia risk, and their association with long-term outcomes. Chapter 5 discusses the treatment of ventricular arrhythmias including indications for implantation of an AICD for primary and for secondary prevention in patients with and without congestive heart failure. Chapter 6 discusses surgical management of atrial fibrillation
Inflammation and Diabetic Cardiomyopathy
Full text linkDiabetes mellitus (DM) is a metabolic syndrome that manifests a low grade of systemic inflammation that contributes to the development of cardiovascular diseases (CVDs). DM is a predominant risk factor for CVDs inducing structural changes in the heart, infiltration of fibrosis, apoptosis, and cardiac remodeling, all leading to myocardial infarction (MI), heart failure (HF), and sudden cardiac death. Furthermore, more than 80% of diabetic patients usually die from heart diseases or diabetic cardiomyopathy (DCM). Currently, HF is one of the main causes of mortality in the world despite advances in drug treatments. According to literature, a strong association exists between chronic inflammation and the development of DCM. In order to have a better appreciation of the effect of diabetes and inflammation on the cardiovascular system (CVS), it is of paramount importance to have a better understanding of diabetes, the physiology of the CVS, and the pathophysiology of DM. Thus, the present review highlights the role of chronic inflammation in the complex interplay between the development of DM and DCM. Our understanding of the process is critical in the discovery of new targeted therapies for DCM and other forms of HF
Management of Dyslipidemia
No full textDyslipidemia is a major risk factor for cardiovascular events, cardiovascular mortality, and all-cause mortality. The earlier in life dyslipidemia is treated, the better the prognosis. The current book is an excellent one on dyslipidemia written by experts on this topic. This book includes 12 chapters including 5 on lipids, 4 on hypercholesterolemia in children, and 3 on the treatment of dyslipidemia. This book should be read by all health care professionals taking care of patients, including pediatricians since atherosclerotic cardiovascular disease begins in childhood
Dyslipidemia: Current Perspectives and Implications for Clinical Practice
No full textDyslipidemia refers to a broad spectrum of various genetic and acquired disorders that affect blood lipid levels and largely contribute to global cardiovascular disease burden. Consistent evidence from epidemiological and clinical studies, supports the key role of the circulating LDL- cholesterol and other apoB containing lipoproteins in atherogenesis. All ApoB-containing lipoproteins with size less than 70 nm can cross the endothelial barrier, particularly in the presence of endothelial dysfunction. Uptake and accumulation of apoB-containing lipoproteins in the arterial wall is a critical initiating event in the development of atherosclerosis. Statin treatment, targeting LDL cholesterol reduction, remains the cornerstone of dyslipidemia management. There are abundant data supporting the concept of ‘the lower LDL-C, the better’ in the primary and secondary cardiovascular disease prevention. This chapter provides an overview of the key insights into the lipid abnormalities associated with an increased risk of CV events particulary in the context of dyslipidemia management in everyday clinical practice. Understanding the important role that metabolic derangements play in the pathogenesis of atherosclerosis pave the way for stronger implementation of current guidelines for CVD risk assessment and prevention
Baseline Hypokalemia and Long-Term Outcomes in Ambulatory Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and New York Heart Association Class III-IV: A Propensity-Matched Study of Beta-Blocker Evaluation of Survival Trial (BEST)
No full textMultimorbidity and outcomes in patients with heart failure and reduced ejection fraction
No full textDuration of heart failure and outcomes in patients with heart failure and reduced ejection fraction
No full text- …
